RecruitingNCT04970056

Pancreatic Cancer Early Detection Consortium


Sponsor

Arbor Research Collaborative for Health

Enrollment

20,000 participants

Start Date

Sep 18, 2020

Study Type

OBSERVATIONAL

Conditions

Summary

The purpose of the Pancreatic Cancer Early Detection (PRECEDE) Consortium is to conduct research on multiple aspects of early detection and prevention of pancreatic ductal adenocarcinoma (PDAC) by establishing a multisite cohort of individuals with family history of PDAC and/or individuals carrying pathogenic/likely pathogenic germline variants (PGVs) in genes linked to PDAC risk for longitudinal follow up.


Eligibility

Min Age: 18 YearsMax Age: 90 Years

Inclusion Criteria29

  • Individuals from the following groups who present for clinical evaluation and assessment of PDAC risk at any of the participating sites can be offered participation in the PRECEDE database:
  • Cohort 1
  • Individuals without history of PDAC meeting any of the following criteria:
  • + relatives with PDAC on same side of family where 2 affected are first degree related to each other and at least 1 affected is first degree related to subject; age 50+ or ≤10 years younger than earliest PDAC in family at time of diagnosis.
  • affected first degree relatives with PDAC; age 50+ or 10 years younger than earliest PDAC in family
  • BRCA1, BRCA2, PALB2, ATM, MLH1, MSH2, MSH6, PMS2, EPCAM pathogenic or likely pathogenic variant AND 1 first or second degree relative with PDAC; age 50+ or 10 years younger than earliest PDAC in family
  • Familial Atypical Moles and Malignant Melanoma (FAMMM) with pathogenic or likely pathogenic CDKN2A variant; age 40+
  • Peutz-Jegher syndrome with STK11 pathogenic or likely pathogenic variant; age 35+
  • Hereditary pancreatitis with PRSS1 pathogenic or likely pathogenic variant and history of pancreatitis; age 40+
  • Cohort 2
  • Individuals without history of PDAC meeting any of the following criteria:
  • ATM, BRCA1, BRCA2, or PALB2 pathogenic or likely pathogenic variant regardless of family history, age 50+
  • + relatives with PDAC on the same side of family, any degree of relation, not meeting other criteria above; age 50+ or 10 years younger than earliest PDAC in family
  • first degree relative with PDAC ≤ age 45; age up to 10 years younger than PDAC diagnosis in family member
  • Cohort 3 Individual meeting criteria for Cohorts 1 or 2 EXCEPT age (i.e. too young to qualify for Cohorts 1 or 2)
  • Cohort 4 Individuals without history of PDAC presenting for evaluation who do not meet any criteria for 1-3, 6, or the Cyst Cohort.
  • Cohort 5 Individuals without history of PDAC who are not otherwise engaged in pancreas surveillance at a participating site may be invited to participate in the PRECEDE database and to donate a biosample (e.g. blood, saliva, and/or buccal swab) for discovery studies. This may include relatives of individuals in Cohorts 1-4,6, and the Cyst Cohort.
  • Cohort 6a
  • Individuals diagnosed with PDAC or pancreatic high-grade dysplasia after enrollment in PRECEDE meeting any of the following criteria:
  • Family history includes at least one first degree relative with PDAC, or 2 relatives with PDAC who are first degree related to each other
  • Personal or family history of a pathogenic or likely pathogenic germline variant in ATM, BRCA1, BRCA2, CDKN2A, EPCAM, MLH1, MSH2, MSH6, PALB2,PMS2, PRSS1, STK11
  • Cohort 6b
  • Individuals with a personal history of PDAC or pancreatic high-grade dysplasia meeting any of the following criteria:
  • Family history includes at least one first degree relative with PDAC, or 2 relatives with PDAC who are first degree related to each other
  • Personal or family history of a pathogenic or likely pathogenic germline variant in ATM, BRCA1, BRCA2, CDKN2A, EPCAM, MLH1, MSH2, MSH6, PALB2,PMS2, PRSS1, STK11
  • Diagnosed ≤ age 45
  • Cohort 6c Individuals with newly diagnosed early stage (stage I or stage II) PDAC seen at a PRECEDE site that do not meet the criteria for 6a or 6b.
  • Cohort 6d Individuals with PDAC seen at a PRECEDE site that do not meet the criteria for 6a, 6b, or 6c.
  • Cyst Cohort Individuals with a personal history of a pancreatic cystic neoplasm not meeting any criteria for Cohorts 1-3 or 6 (no known family history of PDAC, no known pathogenic germline variants linked to PDAC risk)

Exclusion Criteria1

  • Individuals not meeting the criteria above.

Locations(60)

Mayo Clinic Arizona

Phoenix, Arizona, United States

Honor Health Research Institute

Scottsdale, Arizona, United States

Providence Health and Services

Burbank, California, United States

City of Hope

Duarte, California, United States

UC San Diego Moores Cancer Center

La Jolla, California, United States

Cedars-Sinai Medical Center

Los Angeles, California, United States

UCLA Health

Los Angeles, California, United States

Hoag

Newport Beach, California, United States

UC Irvine Health

Orange, California, United States

UC Davis

Sacramento, California, United States

University of California, San Francisco (UCSF)

San Francisco, California, United States

Yale University

New Haven, Connecticut, United States

Mayo Clinic Jacksonville

Jacksonville, Florida, United States

University of Miami

Miami, Florida, United States

Moffitt Cancer Center

Tampa, Florida, United States

Emory University Hospital

Atlanta, Georgia, United States

Illinois CancerCare

Bloomington, Illinois, United States

University of Chicago Medicine

Chicago, Illinois, United States

NorthShore University HealthSystem

Evanston, Illinois, United States

University of Kansas Medical Center

Kansas City, Kansas, United States

Massachusetts General Hospital

Boston, Massachusetts, United States

Umass Memorial Medical Center

Worcester, Massachusetts, United States

University of Michigan

Ann Arbor, Michigan, United States

Beaumont/Corewell Health

Royal Oak, Michigan, United States

University of Nebraska Medical Center

Omaha, Nebraska, United States

Hackensack Meridian Health

Hackensack, New Jersey, United States

Memorial Sloan Kettering Cancer Center

New York, New York, United States

Icahn School of Medicine At Mount Sinai

New York, New York, United States

Columbia University Irving Medical Center

New York, New York, United States

University of Rochester Medical Center

Rochester, New York, United States

White Plains Hospital

White Plains, New York, United States

The Ohio State University

Columbus, Ohio, United States

Oregon Health & Science University

Portland, Oregon, United States

University of Pennsylvania

Philadelphia, Pennsylvania, United States

Fox Chase Cancer Center

Philadelphia, Pennsylvania, United States

University of Pittsburgh Medical Center (Upmc)

Pittsburgh, Pennsylvania, United States

University of Tennessee Graduate School of Medicine

Knoxville, Tennessee, United States

The University of Texas Southwestern Medical Center

Dallas, Texas, United States

MD Anderson Center

Houston, Texas, United States

Huntsman Cancer Institute

Salt Lake City, Utah, United States

Intermountain Health

St. George, Utah, United States

University of Virginia

Charlottesville, Virginia, United States

Inova Schar Cancer Institute

Fairfax, Virginia, United States

VCU Massey Comprehensive Cancer Center

Richmond, Virginia, United States

University of Washington

Seattle, Washington, United States

Epworth HealthCare

Richmond, Victoria, Australia

British Columbia Cancer Agency

Vancouver, British Columbia, Canada

University Health Network

Toronto, Ontario, Canada

McGill University Health Centre

Montreal, Quebec, Canada

Semmelweis University, Institute of Pancreatic Diseases

Budapest, Hungary

Landspitali University Hospital

Reykjavik, Iceland

Sheba Medical Center

Ramat Gan, Israel

Azienda Ospedaliera Universitaria Integrata Verona

Verona, Italy

National Cancer Centre Singapore

Singapore, Singapore

Hospital Clínic de Barcelona

Barcelona, Spain

Hospital Universitari Arnau De Vilanova

Lleida, Spain

Ramón y Cajal University Hospital

Madrid, Spain

National Cheng Kung University Hospital (NCKUH)

Tainan, Taiwan T.o.c., Taiwan

National Taiwan University Hospital

Taipei, Taiwan

University of Liverpool

Liverpool, United Kingdom

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04970056


Related Trials